Pharmaceuticals

Prescription medicines.

23 brands with a current stake on record from a firm in this headquarters filter.

CAPLYTA
CAPLYTA is a treatment for schizophrenia and for depressive episodes associated with bipolar disorder and major depressive disorder. Johnson & Johnson's fiscal 2025 Form 10-K says it was acquired with Intra-Cellular Therapies on April 2, 2025.
- Controlling stakeJohnson & Johnson
CARVYKTI
CARVYKTI is a CAR-T therapy for relapsed or refractory multiple myeloma. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product and says it is licensed and developed in collaboration with Legend Biotech.
- Controlling stakeJohnson & Johnson
CONCERTA
CONCERTA is an extended-release treatment for attention deficit hyperactivity disorder. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.
- Controlling stakeJohnson & Johnson
DARZALEX
DARZALEX is a treatment for multiple myeloma, also sold as DARZALEX FASPRO. Johnson & Johnson's fiscal 2025 Form 10-K says Genmab owns related patent families and Janssen Biotech, a wholly owned subsidiary, has an exclusive license. The royalty rate is 12% to 20% of DARZALEX net sales.
- Controlling stakeJohnson & Johnson
EDURANT
EDURANT is an antiretroviral medicine for HIV, used with other antiretroviral products. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.
- Controlling stakeJohnson & Johnson
ERLEADA
ERLEADA is an androgen receptor inhibitor for prostate cancer. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.
- Controlling stakeJohnson & Johnson
IMBRUVICA
IMBRUVICA is a treatment for certain B-cell malignancies and chronic graft-versus-host disease. Johnson & Johnson's fiscal 2025 Form 10-K says it is developed in collaboration and co-marketed in the United States with Pharmacyclics LLC, an AbbVie company.
- Controlling stakeJohnson & Johnson
INVEGA SUSTENNA
INVEGA SUSTENNA, also sold as XEPLION, and the longer-acting INVEGA TRINZA and TREVICTA, are treatments for schizophrenia. Johnson & Johnson's fiscal 2025 Form 10-K lists them as key Innovative Medicine products.
- Controlling stakeJohnson & Johnson
LAZCLUZE
LAZCLUZE is an oral EGFR inhibitor for non-small cell lung cancer. Johnson & Johnson's fiscal 2025 Form 10-K lists it with RYBREVANT as a key Innovative Medicine product.
- Controlling stakeJohnson & Johnson
OPSUMIT
OPSUMIT, and the combination OPSYNVI, are treatments for pulmonary arterial hypertension. Johnson & Johnson's fiscal 2025 Form 10-K lists them as key Innovative Medicine products.
- Controlling stakeJohnson & Johnson
PREZISTA
PREZISTA is an antiretroviral medicine for HIV. PREZCOBIX and REZOLSTA are darunavir and cobicistat combinations. Johnson & Johnson's fiscal 2025 Form 10-K lists them as key Innovative Medicine products.
- Controlling stakeJohnson & Johnson
REMICADE
REMICADE is a treatment for immune-mediated inflammatory diseases. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.
- Controlling stakeJohnson & Johnson
RYBREVANT
RYBREVANT is a treatment for certain non-small cell lung cancers, also sold as RYBREVANT FASPRO. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.
- Controlling stakeJohnson & Johnson
SIMPONI
SIMPONI is a treatment for rheumatoid arthritis and other inflammatory diseases, also sold as SIMPONI ARIA. Johnson & Johnson's fiscal 2025 Form 10-K lists both as key Innovative Medicine products.
- Controlling stakeJohnson & Johnson
SPRAVATO
SPRAVATO is an esketamine nasal spray used with an oral antidepressant for treatment-resistant depression. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.
- Controlling stakeJohnson & Johnson
STELARA
STELARA is a treatment for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key product and says biosimilar competition was reducing sales.
- Controlling stakeJohnson & Johnson
SYMTUZA
SYMTUZA is a once-daily single-tablet regimen for HIV. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.
- Controlling stakeJohnson & Johnson
TALVEY
TALVEY is a bispecific antibody for relapsed or refractory multiple myeloma. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.
- Controlling stakeJohnson & Johnson
TECVAYLI
TECVAYLI is a bispecific antibody for relapsed or refractory multiple myeloma. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.
- Controlling stakeJohnson & Johnson
TREMFYA
TREMFYA is a treatment for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.
- Controlling stakeJohnson & Johnson